ALLR

Allarity Therapeutics, Inc. [ALLR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALLR Stock Summary

Top 10 Correlated ETFs

ALLR


Top 10 Correlated Stocks

ALLR


In the News

06:00 29 Mar 2024 ALLR

Allarity Therapeutics to Present at Biomarkers 2024

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.

10:07 29 Mar 2024 ALLR

Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?

Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer.

07:00 29 Mar 2024 ALLR

Allarity Therapeutics to Present at Biomarkers Europe 2023

BOSTON , October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity's development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx.

07:52 29 Mar 2024 ALLR

Top 5 Health Care Stocks That Could Blast Off In August - Biolase (NASDAQ:BIOL), Allarity Therapeutics (NASDAQ:ALLR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

02:12 29 Mar 2024 ALLR

Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?

Shares of clinical-stage precision medicine company Allarity Therapeutics (NASDAQ: ALLR ) initially soared to a 60% gain for the midweek session before paring down gains to roughly 30%. Undergirding sentiment was early-stage data evaluating the efficacy of Ixempra — a metastatic breast cancer therapeutic — at multiple sites in Europe.

08:36 29 Mar 2024 ALLR

Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?

Allarity Therapeutics (NASDAQ: ALLR ) stock is falling hard on Wednesday after the clinical-stage pharmaceutical company launched a public offering. That public offering has the company selling up to $20 million in shares, as well as warrants to purchase its stock.

06:30 29 Mar 2024 ALLR

7 Sorry Pharma Stocks to Sell in April Before It's Too Late

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.

08:34 29 Mar 2024 ALLR

Allarity's stock falls after saying enrollment in two clinical trials is slow

Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer.

10:00 29 Mar 2024 ALLR

Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect

Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post-split share for every 35 pre-split shares. The post Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect appeared first on Pulse 2.0.

09:15 29 Mar 2024 ALLR

Why Is Allarity Therapeutics (ALLR) Stock Down 23% Today?

Allarity Therapeutics (NASDAQ: ALLR ) stock is sliding lower on Friday after announcing a reverse stock split. According to a press release, the company plans to enact a one-for-35 reverse stock split.

ALLR Financial details

Company Rating
Neutral
Market Cap
2.17M
Income
-12.8M
Revenue
0
Book val./share
-1.38
Cash/share
0.08
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
-0.09
Forward P/E
-0.2
PEG
-0
P/S
-
P/B
-0.36
P/C
3.76
P/FCF
-0.22
Quick Ratio
0.19
Current Ratio
0.28
Debt / Equity
-0.47
LT Debt / Equity
-
-
-
EPS (TTM)
-175.23
EPS next Y
-1.52
EPS next Q
-0.53
EPS this Y
190.29%
EPS next Y
-99.13%
EPS next 5Y
-99.66%
EPS last 5Y
-45.73%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-61.16%
-
-
-
-
SMA20
-17.5%
SMA50
-32.65%
SMA100
-43.1%
Inst Own
0%
Inst Trans
0%
ROA
-100%
ROE
2181%
ROC
10.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-13%
Shs Outstand
6.18M
Shs Float
5.49M
-
-
-
-
Target Price
-
52W Range
0.317-154.4
52W High
-
52W Low
-
RSI
27.72
Rel Volume
2.79
Avg Volume
124.96K
Volume
349.02K
Perf Week
-12.29%
Perf Month
-25.1%
Perf Quarter
-53.89%
Perf Half Y
-59.85%
-
-
-
-
Beta
0.227
-
-
Volatility
0.02%, 0.04%
Prev Close
-3.8%
Price
0.3011
Change
-2.87%

ALLR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.060000
Net income per share
-127.06-44.76-167.62-2.06-5.98
Operating cash flow per share
-89.23-63.98-94.67-2.16-6.4
Free cash flow per share
-89.3-64-94.67-2.16-6.4
Cash per share
13.452.63125.210.260.08
Book value per share
159.59236.92118.160.24-1.38
Tangible book value per share
-59.88-32.12-58.82-0.98-6.34
Share holders equity per share
159.59236.92118.160.24-1.38
Interest debt per share
37.7217.779.970.510.9
Market cap
1.67B1.67B2.31B3.2B1.1M
Enterprise value
1.67B1.67B2.29B3.2B2.23M
P/E ratio
-115.7-328.41-86.65-199.35-0.09
Price to sales ratio
13.88K0000
POCF ratio
-164.74-229.76-153.43-190.35-0.09
PFCF ratio
-164.61-229.67-153.43-190.15-0.09
P/B Ratio
92.1162.05122.931.69K-0.4
PTB ratio
92.1162.05122.931.69K-0.4
EV to sales
13.88K0000
Enterprise value over EBITDA
-165.57-169.08-81.02-190.62-0.12
EV to operating cash flow
-164.69-229.97-152.2-190.45-0.18
EV to free cash flow
-164.56-229.88-152.2-190.25-0.18
Earnings yield
-0.010-0.01-0.01-10.85
Free cash flow yield
-0.010-0.01-0.01-11.62
Debt to equity
0.050.070.061.98-0.47
Debt to assets
0.030.050.020.260.11
Net debt to EBITDA
0.06-0.150.65-0.1-0.06
Current ratio
0.710.311.020.440.14
Interest coverage
-5.32-40.65-53.22-154.54-36
Income quality
0.71.430.561.051.07
Dividend Yield
000010.02
Payout ratio
0000-0.92
Sales general and administrative to revenue
32.250000
Research and developement to revenue
53.060000
Intangibles to total assets
0.880.910.570.660.83
Capex to operating cash flow
00000
Capex to revenue
-0.070000
Capex to depreciation
-0.16-0.070-0.30
Stock based compensation to revenue
2.780000
Graham number
675.45488.47667.563.3613.63
ROIC
-0.69-0.22-1.34-5.5911.65
Return on tangible assets
-3.68-1.74-1.24-3.21-5.98
Graham Net
-70.04-47.74-66.73-1.28-6.9
Working capital
-1.38M-3.82M335K-6.25M-12.2M
Tangible asset value
-6.79M-3.64M-9.35M-7.66M-12.62M
Net current asset value
-7.36M-4.84M-9.8M-7.69M-12.64M
Invested capital
0.050.070.061.98-0.47
Average receivables
01.39M1.23M1.11M908.5K
Average payables
02.15M1.41M3.47M7.33M
Average inventory
0-1000-672.5K-672.5K0
Days sales outstanding
5.04K0000
Days payables outstanding
08.98K2.4K19.01K83.02K
Days of inventory on hand
00-4.63K00
Receivables turnover
0.070000
Payables turnover
00.040.150.020
Inventory turnover
00-0.0800
ROE
-0.8-0.19-1.42-8.54.33
Capex per share
-0.07-0.03000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-10.4-165.73-6.39-2.24-0.87
Operating cash flow per share
-8.96-168.89-6.7-2.17-0.84
Free cash flow per share
-9.03-168.89-6.7-2.17-0.84
Cash per share
7.4415.561.130.570.08
Book value per share
6.93-17.89-1.94-1.37-1.38
Tangible book value per share
-28.07-530.26-28.03-5.19-6.34
Share holders equity per share
6.93-17.89-1.94-1.37-1.38
Interest debt per share
14.11205.194.380.460.77
Market cap
112.31M1.27M2.46M1.85M1.1M
Enterprise value
114.02M4.78M3.53M1.62M2.23M
P/E ratio
-9.89-0.1-0.26-0.08-0.16
Price to sales ratio
00000
POCF ratio
-45.92-0.4-0.98-0.34-0.66
PFCF ratio
-45.58-0.4-0.98-0.34-0.66
P/B Ratio
59.42-3.76-3.4-0.55-0.4
PTB ratio
59.42-3.76-3.4-0.55-0.4
EV to sales
00000
Enterprise value over EBITDA
-35.93-1.31-0.85-0.37-0.46
EV to operating cash flow
-46.61-1.49-1.41-0.3-1.33
EV to free cash flow
-46.27-1.49-1.41-0.3-1.33
Earnings yield
-0.03-2.47-0.97-3-1.57
Free cash flow yield
-0.02-2.51-1.02-2.91-1.52
Debt to equity
1.98-11.2-2.06-0.35-0.47
Debt to assets
0.260.30.110.080.11
Net debt to EBITDA
-0.54-0.96-0.260.05-0.23
Current ratio
0.440.260.290.280.14
Interest coverage
-58.19-39.77-29.27130.18-21.21
Income quality
0.860.951.051.210.97
Dividend Yield
0.010.131.8400
Payout ratio
-0.55-0.05-1.900
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.660.760.720.680.83
Capex to operating cash flow
0.010000
Capex to revenue
00000
Capex to depreciation
-90000
Stock based compensation to revenue
00000
Graham number
40.26258.2516.718.35.19
ROIC
-1.08-0.99-5.7623.53
Return on tangible assets
-0.57-1.05-0.64-1.26-0.86
Graham Net
-36.55-654.92-31.89-6.24-6.9
Working capital
-6.25M-8.62M-8.98M-11.36M-12.2M
Tangible asset value
-7.66M-10.05M-10.44M-12.84M-12.62M
Net current asset value
-7.69M-10.08M-10.46M-12.87M-12.64M
Invested capital
1.98-11.2-2.06-0.35-0.47
Average receivables
1.18M1.1M1.47M1.62M1.29M
Average payables
5.48M6.35M7.27M7.22M7.38M
Average inventory
311K-666.5K-14.5K-164K-816K
Days sales outstanding
00000
Days payables outstanding
140.65K29.02K40.45K31.74K84.16K
Days of inventory on hand
0-6K6.52K-8.16K0
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
0-0.020.01-0.010
ROE
-1.59.273.291.640.63
Capex per share
-0.070000

ALLR Frequently Asked Questions

What is Allarity Therapeutics, Inc. stock symbol ?

Allarity Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol ALLR

What is Allarity Therapeutics, Inc. stock quote today ?

Allarity Therapeutics, Inc. stock price is $0.3011 today.

Is Allarity Therapeutics, Inc. stock public?

Yes, Allarity Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap